3 reasons why I think NIB shares could still be a buy

NIB has a lot of things going for it.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Ltd (ASX: NHF) share price has had a rather successful year so far in 2023. Since the start of the year, NIB shares have risen a pleasing 9.07%, going from $7.61 each to Monday's market close price of $8.30. 

That compares favourably against the S&P/ASX 200 Index (ASX: XJO), which is up around 5.19% over the same period:

NIB shares are also up 13.85% over the past 12 months. 

But this ASX 200 insurance provider could still be worth a buy today, despite the gains the company has already booked over the past seven months or so. Here are three reasons why.

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,

Image source: Getty Images

3 reasons that NIB shares could still be a buy today

NIB shares: A major player in a government-supported industry

Most Australians would be at least somewhat familiar with private health insurance and its role in our healthcare system. NIB is a major provider of private health insurance services in Australia, with around a 9.4% market share.

Private health insurance is one of the few products that the government pushes customers into. If you earn above a certain income threshold, you could get penalised with extra tax bills if you don't hold an eligible policy.

Few companies can say that the government actively heard customers their way. But NIB can, making it a compelling reason to consider this company in my view.

A company with strong fundamentals

The best ASX shares tend to display an ability to grow revenue, earnings and profits at a compounding rate over time. NIB has shown it has what it takes to deliver in this arena. Its most recent half-yearly earnings report, covering the six months to 31 December 2022, revealed a 9.3% increase in revenues to $1.5 billion.

Earnings per share (EPS) was up by an even rosier 12.4% to 20 cents, while NIB's net profit after tax (NPAT) metric rose 12.8% to $91.6 million. This all enabled NIB to jack up its interim dividend by 18.2% to 13 cents per share, fully franked.

Dividend potential

Speaking of dividends, NIB is one of ASX's best companies if you want dividend income from the healthcare sector. For one, the company currently sports a robust trailing dividend yield of 2.9%, which comes fully franked.

That's a fairly decent dividend yield on the ASX today, especially from a healthcare stock. But NIB shares have also shown an ability to increase their dividends over time. We've already noted that this year's interim dividend was a pleasing 18.2% hike over what investors received last year.

It's also important to consider that the 24 cents per share that shareholders bagged in 2021, as well as the 22 cents per share that were paid out in 2022, were massive increases over the 13 cents per share investors got in 2019, and the 14 cents per share doled out in 2020. And back in 2012, shareholders received just 4.3 cents per share.

So the dividends from NIB are certainly going in the right direction.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Orthocell caps 26% surge this week with first US Military Surgery

The company's commercial rollout is off to a good start.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

This ASX health tech stock just hit a new record high. Could it go even higher?

Morgans believes there's still upside to be had.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »